| Trade Names: | |
| Synonyms: | |
| Status: | Approved (1968) |
| Entry Type: | Small molecule |
| Molecule Category: | Salt |
| UNII: | M6Q1EO9TD0 |
| Parent Compound: | AMANTADINE |
Structure
| InChI Key | WOLHOYHSEKDWQH-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C10H18ClN |
| Molecular Weight | 187.71 |
| AlogP | 1.91 |
| Hydrogen Bond Acceptor | 1.0 |
| Hydrogen Bond Donor | 1.0 |
| Number of Rotational Bond | 0.0 |
| Polar Surface Area | 26.02 |
| Molecular species | BASE |
| Aromatic Rings | 0.0 |
| Heavy Atoms | 11.0 |
Pharmacology
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Ion channel
Ligand-gated ion channel
Ionotropic glutamate receptor
NMDA receptor
|
- | 75000 | - | - | - | |
|
Ion channel
Other ion channel
Miscellaneous ion channel
Type A influenza virus matrix-2 channel family
|
- | - | - | - | 0-35 | |
|
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC21/SLCO family of organic anion transporting polypeptides
|
- | - | - | - | 61 |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Influenza, Human | 4 | D007251 | FDA |
| Severe Acute Respiratory Syndrome | 3 | D045169 | ClinicalTrials |
| Multiple Sclerosis | 3 | D009103 | ClinicalTrials |
| Brain Injuries | 2 | D001930 | ClinicalTrials |
| Hepatitis C | 2 | D006526 | ClinicalTrials |
| Psychotic Disorders | 1 | D011618 | ClinicalTrials |
| Mood Disorders | 1 | D019964 | ClinicalTrials |
| Schizophrenia | 1 | D012559 | ClinicalTrials |
Related Entries
Adverse Reactions
System Organ Classification (SOC)
Cross References
| Resources | Reference |
|---|---|
| ChEBI | 2619 |
| ChEMBL | CHEMBL1569 |
| EPA CompTox | DTXSID50874031 |
| FDA SRS | M6Q1EO9TD0 |
| Guide to Pharmacology | 4128 |
| KEGG | C07939 |
| PDB | 308 |
| PubChem | 64150 |
| SureChEMBL | SCHEMBL40713 |
| ZINC | ZINC00968256 |
CONTENTS